Trump pushes faster FDA path for psychedelic therapies
TL;DR Summary
Trump announced an executive order to accelerate FDA review of psychedelic drugs like ibogaine, earmarking $50 million for federal research and opening a path to reclassify these drugs after successful trials, signaling a push to expand access to psychedelic treatments.
- Trump announces reforms to accelerate access to psychedelic drug treatments The Guardian
- Trump Signs Executive Order to Loosen Restrictions on Psychedelic Drugs The New York Times
- Trump accelerates research on psychedelic treatments and asks, ‘Can I have some?’ CNN
- Trump signs order to accelerate access to psychedelic drug treatments Reuters
- Trump signs executive order on psychedelic drugs — with Joe Rogan by his side MS NOW
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
1 min
vs 2 min read
Condensed
84%
254 → 40 words
Want the full story? Read the original article
Read on The Guardian